The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics.
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Cybin's bought deal financing has been upsized to CAD$30 million.
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
